Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00879606 · ClinicalTrials.gov registry record · Phase 2
Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome
A Phase 2 study of Sepsis and Acute Respiratory Distress Syndrome, sponsored by Altor BioScience.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 20
- Study locations
NCT00879606: Completed Phase 2 study of Sepsis and Acute Respiratory Distress Syndrome, sponsored by Altor BioScience.
NCT00879606 is a Phase 2 study of Sepsis and Acute Respiratory Distress Syndrome that has completed, run by Altor BioScience. The registered enrollment target is 150 participants, below the 6,563-participant average among 90 other Sepsis trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00879606, a Phase 2 study of Sepsis and Acute Respiratory Distress Syndrome, has completed, sponsored by Altor BioScience.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a prospective, randomized (1:1), double-blind, multi-center, Phase II clinical study to test the safety and efficacy of a recombinant chimeric anti-tissue factor antibody (ALT-836) versus placebo in patients with sepsis and acute lung injury/acute respiratory distress syndrome (ALI/ARDS). This study was divided into two parts and the first part of the study has been completed. In the first part of the study, sixty patients were randomized at a 1:1 ratio to receive one dose of the study drug or placebo. In the second part of the study, ninety patients will be randomized at a 1:1 ratio to receive a multi-dose treatment regimen of single doses every 72 hours up to a maximum of 4 doses of the study drug or placebo, provided there are no safety concerns.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ALT-836
Study Locations (20)
California
- Los Angeles County and USC Medical Center - Los Angeles
- UC Davis Medical Center - Sacramento
- Stanford University - Stanford
Illinois
- Northwestern University - Chicago
- West Suburban Hospital Medical Center - Oak Park
- Illinois Lung and Critical Care Institute - Peoria
Missouri
- Saint Luke's Hospital - Kansas City
- Saint Louis University - St Louis
- Mercy Hospital St. Louis - St Louis
North Carolina
- Carolinas Medical Center - Charlotte
- Piedmont Respiratory Research Foundation - Greensboro
- Wake Forest University - Winston-Salem
Kentucky
- Kentucky Lung Clinic - Hazard
- University of Louisville-Division of Pulmonary and Critical Care - Louisville
New York
- Mount Sinai Medical Center - New York
- Memorial Sloan-Kettering Cancer Center - New York
Connecticut
- Yale University - New Haven
Iowa
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2009-04 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
What the finished NCT00879606 record still lists
NCT00879606 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 6,563-participant average among 90 other Sepsis trials with a reported enrollment target (98% lower).
The record links to 3 conditions, with Sepsis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00879606 names 20 study sites across 10 states, led by California, Illinois, Missouri.
Frequently Asked Questions
What is clinical trial NCT00879606 about?
NCT00879606 is a clinical study titled "Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome". This is a prospective, randomized (1:1), double-blind, multi-center, Phase II clinical study to test the safety and efficacy of a recombinant chimeric anti-tissue factor antibody (ALT-836) versus placebo in patients with sepsis and acute lung injury/acute respiratory distress syndrome (ALI/ARDS). Th...
What is the current status of trial NCT00879606?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2009-04. Estimated completion is 2013-01.
What conditions does trial NCT00879606 study?
This clinical trial studies the following conditions: Sepsis, Acute Respiratory Distress Syndrome, Acute Lung Injury.
What interventions are being tested in trial NCT00879606?
The interventions under investigation include: Placebo (DRUG), ALT-836 (DRUG).
Who is sponsoring clinical trial NCT00879606?
This trial is sponsored by Altor BioScience, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00879606 being conducted?
This trial has 20 study locations across California, Connecticut, Illinois, Iowa, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sepsis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00879606's enrollment target sits among peer trials
150 48th of 90 higher than 41 of 90 other Sepsis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sepsis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial
RECRUITING · Phase 2
-
MID-STEP (MIDodrine for Sepsis Treatment and Early vasoPressor Weaning) Trial
RECRUITING · Phase 2
-
A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.
RECRUITING · Phase 2
-
An Acupuncture Study for People At High Risk for Sepsis
RECRUITING · Phase 2
-
Intravenous Immune Globulin (IVIG) to Prevent Neonatal Infection
COMPLETED · Phase 2
-
Inulin for Infections in the Intensive Care Unit
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia